RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/21050904/ below:

Worsening disparities in HPV vaccine utilization among 19-26 year old women

. 2011 Jan 10;29(3):528-34. doi: 10.1016/j.vaccine.2010.10.051. Epub 2010 Nov 2. Worsening disparities in HPV vaccine utilization among 19-26 year old women

Affiliations

Affiliation

¹ University of Michigan, Department of Pediatrics, Child Health Evaluation, Research Unit, Ann Arbor, MI 48109-5456, USA. adempsey@umich.edu

PMID: 21050904
PMCID: PMC3013617
DOI: 10.1016/j.vaccine.2010.10.051

Item in Clipboard

Worsening disparities in HPV vaccine utilization among 19-26 year old women

Amanda Dempsey et al. Vaccine. 2011.

. 2011 Jan 10;29(3):528-34. doi: 10.1016/j.vaccine.2010.10.051. Epub 2010 Nov 2. Affiliation

¹ University of Michigan, Department of Pediatrics, Child Health Evaluation, Research Unit, Ann Arbor, MI 48109-5456, USA. adempsey@umich.edu

PMID: 21050904
PMCID: PMC3013617
DOI: 10.1016/j.vaccine.2010.10.051

Item in Clipboard

Abstract

We evaluated the characteristics associated with uptake of HPV vaccine by 19-26 year old women seen in primary care university-based clinics. Of the 11,545 women analyzed only 18% had initiated the 3-dose vaccine series. Series completion among the sample overall was only 10% in the 30 month study period. Decreased series initiation was associated with older age, public insurance, white race and non-family medicine specialty. Decreased series completion was associated with public insurance and African American race. Utilization disparities by race and insurance worsened over time suggesting that the highest risk populations of women were not getting vaccinated.

PubMed Disclaimer

Figures
Figure 1

Cumulative proportion of women vaccinated…

Figure 1

Cumulative proportion of women vaccinated overall, and subdivided by race, insurance type and…

Figure 1

Cumulative proportion of women vaccinated overall, and subdivided by race, insurance type and medical specialty of appointment.

Cited by

Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest.
Verdenius I, Harper DM, Harris GD, Griffith RS, Wall J, Hempstead LK, Malnar GJ, Bekkers RL. Verdenius I, et al. PLoS One. 2013 Aug 8;8(8):e71295. doi: 10.1371/journal.pone.0071295. eCollection 2013. PLoS One. 2013. PMID: 23951123 Free PMC article.

References

1. U.S. Food and Drug Administration Product Approval Information - Licensing Action, Gardasil. 2006. Aug 1, 2006. Available from: http://www.fda.gov/cber/products/hpvmer060806qa.htm.
1. Markowitz LE, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2007;56(RR-2):1–24. - PubMed
1. Dempsey A, Cohn L, Dalton VA, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a unveristy-based health system. Vaccine. 2010;28(4):989–995. - PMC - PubMed
1. Chao C, et al. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc. 2009;84(10):864–70. - PMC - PubMed
1. Neubrand TP, et al. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr (Phila) 2009;48(9):966–969. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3